Cilostazol Could Ameliorate Platelet Responsiveness to Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention

概要

論文の詳細を見る
Background Cilostazol increases the cyclic adenosine monophosphate levels in platelets and might ameliorate the antiplatelet activity of clopidogrel. This study investigated the additional effect of cilostazol on platelet aggregation measured by a VerifyNow analyzer and soluble CD40 ligand (sCD40L) as a marker of activated platelet in patients undergoing primary percutaneous coronary intervention (PCI). Methods and Results Sixty cases of primary PCI were randomly assigned to dual (aspirin and clopidogrel) or triple (dual plus cilostazol) therapy. The antiplatelet effects of aspirin and clopidogrel were evaluated by VerifyNow^<TM> tests. The plasma sCD40L levels at admission, 24h and 21 days were measured by the ELISA method. The arachidonic acid induced platelet aggregation was similar in both groups. However, the triple group had a significantly lower P2Y12 reaction unit (dual 208.8±69.0 vs triple 168.2±79.2, p=0.041) and higher % inhibition of adenosine diphosphate (ADP)-induced platelet aggregation (dual 23.8±21.4% vs triple 40.5±21.0%, p=0.004). In the multivariate analysis, cilostazol was a negative predictor for low responders to clopidogrel (95% confidence interval 0.067-0.711). The plasma sCD40L levels were not significantly different between the 2 groups at the same point of time. Conclusions The addition of cilostazol to the combination of aspirin plus clopidogrel significantly increases the inhibition of ADP-induced platelet aggregation. However, there was no additive effect on aspirin-induced antiplatelet activity or lowering of sCD40L.
社団法人日本循環器学会の論文
2007-11-20

Cilostazol Could Ameliorate Platelet Responsiveness to Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention

スポンサーリンク

概要

著者

関連論文

スポンサーリンク